Immunogenicity of engineered antibodies

William Ying Khee Hwang1, Jefferson Foote

  • 1Singapore Health Services, Singapore General Hospital, Singapore.

Administration of a therapeutic antibody can lead to an anti-antibody response (AAR). Much effort has been applied to engineering antibodies with as little as possible non-human structure to minimize such responses. Here, we review reported AAR to murine, mouse-human chimeric, and humanized antibodies. Replacement of mouse immunoglobulin constant regions with human ones effects the largest immunogenicity reduction. Humanization of variable domains effects a further decrease.